AI Science Tracker
EN

Fudan University Shanghai Cancer Center

5 discoveries from 2022 to 2026

Discoveries

Ascites-image models stratify recorded platinum resistance in ovarian cancer

Source check: Source checked. Not independent scientific confirmation.

Finding: OVCAP analyzed pretreatment ascites cytology from 438 women with advanced epithelial ovarian cancer. Internal and two additional-site validation cohorts yielded resistance-classification AUCs of 0.894, 0.863 and 0.828. This retrospective treatment-response study does not establish that model-guided treatment improves outcomes.

Technology: Prov-GigaPath features, TransMIL and multi-scale late fusion

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Pathology foundation-model embeddings and attention-based multiple-instance learning estimated response risk from image patches; trained multi-scale fusion combined the prediction streams.
Test and result
The 2019–2023 cohort comprised 367 Xuhui-campus cases split into 254 training and 113 internal-validation patients, plus 51 Pudong-campus and 20 Northern-Jiangsu validation patients. Patient-level three-fold training cross-validation selected among 15 encoders and hyperparameters. The retained multi-scale predictor was applied unchanged to the held-out cohorts. Resistance meant progression during therapy or recurrence/progression within six months after completing platinum treatment; the reported internal/external AUCs were .894/.863/.828.
Limitation / still unknown
The three sites represent two institutions; one additional-site cohort shares the same cancer center as development. The smallest cohort contains only 20 people. Retrospective selection of patients with evaluable outcomes, histologic concentration in high-grade serous cancer and preparation/scanner differences constrain transfer. AUCs are not treatment-benefit estimates. Attention-selected morphology and integrated single-cell associations are hypothesis-generating, not established mechanisms of resistance. Clinical vignettes and comparison with later-available kinetic biomarkers do not demonstrate prospective clinical utility.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13330694/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 21 Nov 2026. Review scope: Original model/clinical cohort, outcome definition, patient-level training selection and held-out Results; exploratory biological interpretation and clinical benefit kept bounded..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Stemness-based gastric cancer classification by machine learning for precision diagnosis and treatment of gastric cancer.

Source check: Source checked. Not independent scientific confirmation.

Finding: OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes; a 12-gene ML model was checked on an external cohort. Predicted immunotherapy/chemotherapy differences are in-silico and not measured treatment responses. The result is reported in Journal of Gastrointestinal Oncology. The study does not establish generalization beyond its reported setting or prospective real-world benefit.

Technology: OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes
Test and result
OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes; a 12-gene ML model was checked on an external cohort. Predicted immunotherapy/chemotherapy differences are in-silico and not measured treatment responses.
Limitation / still unknown
Independent replication and prospective real-world benefit are not established in the reviewed study.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12598432/ · https://europepmc.org/article/MED/41220758

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response

Source check: Source checked. Not independent scientific confirmation.

Finding: Primary article reports multi-omics and ten-ML-algorithm work identifying bladder-cancer PANoptosis subtypes and a prognostic signature. External cohorts support survival associations; immunotherapy response is computationally inferred. This record is limited to the study result and does not establish independent replication or real-world benefit.

Technology: Ten-machine-learning-algorithm panel

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
transcriptomic/spatial data, subtype analysis and ten ML algorithms for the PANoptosis prognostic signature.
Test and result
Primary article reports multi-omics and ten-ML-algorithm work identifying bladder-cancer PANoptosis subtypes and a prognostic signature. External cohorts support survival associations; immunotherapy response is computationally inferred.
Limitation / still unknown
No prospective clinical benefit or broader external validity is established by the documented study.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.32604/or.2025.064331

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Prediction of 5-year progression-free survival in advanced nasopharyngeal carcinoma with pretreatment PET/CT using multi-modality deep learning-based radiomics.

Source check: Source checked. Not independent scientific confirmation.

Finding: The model separated high- and low-risk groups in internal and external cohorts; external cohort comprised 87 patients. External replication and prospective utility were not established in the reviewed material.

Technology: A 3D multimodal deep-radiomics model combined pretreatment PET/CT and clinical stage to estimate five-year PFS.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
A 3D multimodal deep-radiomics model combined pretreatment PET/CT and clinical stage to estimate five-year PFS.
Test and result
The model separated high- and low-risk groups in internal and external cohorts; external cohort comprised 87 patients.
Limitation / still unknown
External replication, causal effects and prospective utility were not established in the reviewed material.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.899351/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.

Source check: Source checked. Not independent scientific confirmation.

Finding: TCGA cohort (230 samples) supports an SVM platinum-response classifier and LASSO-Cox survival model, with GEO used for validation. External replication and prospective utility were not established in the reviewed material.

Technology: Machine-learning signatures predict platinum response and survival in ovarian cancer.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Machine-learning signatures predict platinum response and survival in ovarian cancer.
Test and result
TCGA cohort (230 samples) supports an SVM platinum-response classifier and LASSO-Cox survival model, with GEO used for validation.
Limitation / still unknown
External replication, causal effects and prospective utility were not established in the reviewed material.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8973612/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.